Odessa Addison1,2, Rishi Kundi3, Alice S Ryan1,4, Andrew P Goldberg4, Richa Patel3, Brajesh K Lal3, Steven J Prior1,4. 1. a Department of Veterans Affairs and Veterans Affairs Medical Center Baltimore, Geriatric Research , Education and Clinical Center (GRECC) , Baltimore , MD , USA. 2. b Department of Physical Therapy and Rehabilitation Science , University of Maryland School of Medicine , Baltimore , MD , USA. 3. c Department of Surgery, Division of Vascular Surgery , University of Maryland and Baltimore VA Medical Center , Baltimore , MD , USA. 4. d Department of Medicine, Division of Gerontology and Geriatric Medicine , University of Maryland School of Medicine , Baltimore , MD , USA.
Abstract
PURPOSE: The study is to compare the Modified Physical Performance Test (MPPT) and Short Physical Performance Battery (SPPB) as metrics of mobility and function in older men with peripheral arterial disease (PAD). MATERIALS AND METHODS: A total of 51 men (55-87 years) with PAD underwent functional testing including the SPPB, MPPT, Walking Impairment Questionnaire (WIQ), stair ascent, and 6-min walk distance. Individuals were grouped according to SPPB and MPPT scores as not limited on either, limited only on the MPPT, or limited on both. RESULTS: The MPPT identified a higher proportion of patients as being functionally limited than the SPPB (p < 0.001). Men identified as limited only by the MPPT, and not the SPPB, were subsequently confirmed to have lower function on all measures compared to those not identified as limited by either the SPPB or the MPPT (p < 0.02). CONCLUSIONS: These findings suggest the MPPT is an appropriate measure to identify early declines in men with PAD and may identify global disability better than SPPB. Implications for rehabilitation Individuals with peripheral arterial disease have low activity levels and are at risk for a loss of independence and global disability. Early detection of decline in mobility and global function would allow for interventions before large changes in ambulatory ability or a loss of functional independence occur. This study shows the Modified Physical Performance Test may be an appropriate test to identify early decline in function in men with peripheral arterial disease.
PURPOSE: The study is to compare the Modified Physical Performance Test (MPPT) and Short Physical Performance Battery (SPPB) as metrics of mobility and function in older men with peripheral arterial disease (PAD). MATERIALS AND METHODS: A total of 51 men (55-87 years) with PAD underwent functional testing including the SPPB, MPPT, Walking Impairment Questionnaire (WIQ), stair ascent, and 6-min walk distance. Individuals were grouped according to SPPB and MPPT scores as not limited on either, limited only on the MPPT, or limited on both. RESULTS: The MPPT identified a higher proportion of patients as being functionally limited than the SPPB (p < 0.001). Men identified as limited only by the MPPT, and not the SPPB, were subsequently confirmed to have lower function on all measures compared to those not identified as limited by either the SPPB or the MPPT (p < 0.02). CONCLUSIONS: These findings suggest the MPPT is an appropriate measure to identify early declines in men with PAD and may identify global disability better than SPPB. Implications for rehabilitation Individuals with peripheral arterial disease have low activity levels and are at risk for a loss of independence and global disability. Early detection of decline in mobility and global function would allow for interventions before large changes in ambulatory ability or a loss of functional independence occur. This study shows the Modified Physical Performance Test may be an appropriate test to identify early decline in function in men with peripheral arterial disease.
Authors: C Casanova; B R Celli; P Barria; A Casas; C Cote; J P de Torres; J Jardim; M V Lopez; J M Marin; M Montes de Oca; V Pinto-Plata; A Aguirre-Jaime Journal: Eur Respir J Date: 2010-06-04 Impact factor: 16.671
Authors: Daniel C Bittel; Adam J Bittel; Lori J Tuttle; Mary K Hastings; Paul K Commean; Michael J Mueller; W Todd Cade; David R Sinacore Journal: J Diabetes Complications Date: 2014-11-13 Impact factor: 2.852
Authors: M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin Journal: JAMA Date: 2001-10-03 Impact factor: 56.272
Authors: Mary M McDermott; Jack M Guralnik; Lu Tian; Kiang Liu; Luigi Ferrucci; Yihua Liao; Leena Sharma; Michael H Criqui Journal: J Am Coll Cardiol Date: 2009-03-24 Impact factor: 24.094
Authors: Mary McGrae McDermott; Kiang Liu; Philip Greenland; Jack M Guralnik; Michael H Criqui; Cheeling Chan; William H Pearce; Joseph R Schneider; Luigi Ferrucci; Lillian Celic; Lloyd M Taylor; Ed Vonesh; Gary J Martin; Elizabeth Clark Journal: JAMA Date: 2004-07-28 Impact factor: 56.272
Authors: Mary M McDermott; Lu Tian; Kiang Liu; Jack M Guralnik; Luigi Ferrucci; Jin Tan; William H Pearce; Joseph R Schneider; Michael H Criqui Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094
Authors: Mary M McDermott; Kathryn Domanchuk; Alan Dyer; Philip Ades; Melina Kibbe; Michael H Criqui Journal: J Vasc Surg Date: 2009-01-09 Impact factor: 4.860
Authors: Tatiana V D Sanses; Sharee Pearson; Derik Davis; Chi Chiung Grace Chen; Soren Bentzen; Jack Guralnik; Holly E Richter; Alice S Ryan Journal: Int Urogynecol J Date: 2020-11-17 Impact factor: 2.894